Brand Intelligence Graphcompany
Company Overview
About Labcorp
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
Business Model & Competitive Advantage
Labcorp's clinical laboratory services model creates competitive advantages through the nationwide patient service center network and advanced specialty laboratory infrastructure: building a nationwide laboratory network requires 2,000+ patient service center locations for specimen collection, regional hub laboratories for routine testing turnaround (24-48 hour results for common blood work), and specialty reference laboratories for complex esoteric testing — a $2+ billion infrastructure investment that creates a natural duopoly with Quest Diagnostics as the only two laboratories capable of serving national health system laboratory outsourcing contracts. Hospital health systems contracting Labcorp to operate or manage their outreach laboratory (hospital-branded testing for outpatient and physician office patients in the surrounding community) generates high-volume recurring revenue from the health system's patient population without Labcorp incurring the capital cost of managing hospital inpatient testing infrastructure. Labcorp's integrated data platform (diagnostic results in Labcorp's secure portal accessible to patients and physicians, integrated with Epic and Cerner EHR systems) creates clinical workflow integration that makes switching laboratory providers disruptive.
Competitive Landscape 2025–2026
In 2025, Labcorp competes in clinical laboratory services against Quest Diagnostics (NYSE: DGX, $9.6B revenue, national laboratory duopoly partner and competitor), hospital reference laboratories (Cleveland Clinic, Mayo Clinic, Johns Hopkins laboratories accepting external referrals), and specialty molecular diagnostics companies (Genomic Health/Exact Sciences for oncology testing, Natera for genetic testing) for routine laboratory testing volume, health system laboratory outsourcing contracts, and oncology/specialty molecular testing market share. The laboratory consolidation trend (independent physician office labs sending testing to Labcorp and Quest as regulatory complexity and equipment costs favor central reference testing) continues to drive volume growth into the national lab duopoly. The oncology testing expansion (comprehensive genomic profiling, minimal residual disease testing, liquid biopsy for cancer surveillance) represents the highest-growth specialty testing category as FDA-cleared next-generation sequencing panels (Labcorp's Plasma Focus and FoundationOne integration) create new testing occasions across the cancer care continuum. The 2025 strategy focuses on health system laboratory services contracting growth, oncology molecular testing volume, and consumer-direct testing platform expansion.
The Labcorp Story
Founders
Recent Activity
View all →Quarterly Report filed 2026-05-04
Material Event filed 2026-04-30
Proxy Statement filed 2026-04-10
Material Event filed 2026-04-09
Material Event filed 2026-03-31
Gail Bromage Gail Bromage is a quality director who specializes in quality management systems and regulatory readiness. Gail has been with Labcorp since May of 2000. Gail’s focus is on strengthening the quality management systems in oncology, pathology and women’s health and genetics. Gail believes that Quality’s role is supporting both the internal and external customer while putting our patients at the center of all we do. Gail previously worked in the clinical laboratory field as a cytogenetic technologist lead specializing in genetics and oncology after graduating from Grove City College in Pennsylvania. She holds certifications from the American Society for Quality as a certified quality auditor (CQA) and quality manager of operational excellence (CMQOE), is a Six Sigma Green Belt and is licensed as a cytogenetic technologist (CG) by the American Society of Clinical Pathologists. When she is not working, Gail can be found reading, taking hikes or walks on the bea
Company Timeline
Major milestones in Labcorp's journey
Leadership Team
Meet the leaders behind Labcorp
Adam Schechter
Adam Schechter has served as CEO of Labcorp since 2019 and Chairman of the Board since May 2020. He leads the company's strategic vision to improve health and improve lives through innovative diagnostic solutions and pharmaceutical development services.
Julia Wang
Julia Wang joined Labcorp as Executive Vice President and Chief Financial Officer in December 2024. She oversees the company's financial strategy, operations, and reporting.
Bola Oyegunwa, Ph.D.
Dr. Bola Oyegunwa has served as Labcorp's Executive Vice President and Chief Information and Technology Officer since November 2024. She leads the company's technology strategy and digital transformation initiatives.
Mark Schroeder
Mark Schroeder has served in his current role since 2023, overseeing Labcorp's diagnostics operations and ensuring operational excellence across the company's global laboratory network.
Megan Bailey
Megan Bailey leads Labcorp's Central Laboratory Services and International operations, managing the company's pharmaceutical development services and global expansion initiatives since 2024.
Anita Graham
Anita Graham has served as Executive Vice President and Chief Human Resources Officer since 2023, leading talent management, diversity and inclusion initiatives, and employee engagement across Labcorp's 70,000+ workforce.
Sandy van der Vaart
Sandy van der Vaart has served as Executive Vice President, Chief Legal Officer and Corporate Secretary since February 2020, overseeing legal affairs, compliance, and corporate governance.
Amy Summy
Amy Summy has served as EVP, Chief Marketing Officer and Consumer Business Lead since March 2020, leading Labcorp's consumer-facing initiatives including Labcorp OnDemand and brand strategy.
Key Differentiators
Market Leader
Labcorp is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $13.1B in revenue, Labcorp operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Labcorp with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Labcorp? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Labcorp Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Labcorp vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →